Biosimilars-EMEA Market Status and Trend Report 2013-2023
Report Summary
Biosimilars-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Biosimilars industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Biosimilars 2013-2017, and development forecast 2018-2023
Main market players of Biosimilars in EMEA, with company and product introduction, position in the Biosimilars market
Market status and development trend of Biosimilars by types and applications
Cost and profit status of Biosimilars, and marketing status
Market growth drivers and challenges
The report segments the EMEA Biosimilars market as:
EMEA Biosimilars Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Biosimilars Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Antibody
Hormone
Growth Factors
EMEA Biosimilars Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
EMEA Biosimilars Market: Players Segment Analysis (Company and Product introduction, Biosimilars Sales Volume, Revenue, Price and Gross Margin):
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Sun
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Biosimilars-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Biosimilars industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Biosimilars 2013-2017, and development forecast 2018-2023
Main market players of Biosimilars in EMEA, with company and product introduction, position in the Biosimilars market
Market status and development trend of Biosimilars by types and applications
Cost and profit status of Biosimilars, and marketing status
Market growth drivers and challenges
The report segments the EMEA Biosimilars market as:
EMEA Biosimilars Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Biosimilars Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Antibody
Hormone
Growth Factors
EMEA Biosimilars Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
EMEA Biosimilars Market: Players Segment Analysis (Company and Product introduction, Biosimilars Sales Volume, Revenue, Price and Gross Margin):
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Sun
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF BIOSIMILARS
1.1 Definition of Biosimilars in This Report
1.2 Commercial Types of Biosimilars
1.2.1 Antibody
1.2.2 Hormone
1.2.3 Growth Factors
1.3 Downstream Application of Biosimilars
1.3.1 Tumor
1.3.2 Diabetes
1.3.3 Cardiovascular
1.3.4 Hemophilia
1.3.5 Other
1.4 Development History of Biosimilars
1.5 Market Status and Trend of Biosimilars 2013-2023
1.5.1 EMEA Biosimilars Market Status and Trend 2013-2023
1.5.2 Regional Biosimilars Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Biosimilars in EMEA 2013-2017
2.2 Consumption Market of Biosimilars in EMEA by Regions
2.2.1 Consumption Volume of Biosimilars in EMEA by Regions
2.2.2 Revenue of Biosimilars in EMEA by Regions
2.3 Market Analysis of Biosimilars in EMEA by Regions
2.3.1 Market Analysis of Biosimilars in Europe 2013-2017
2.3.2 Market Analysis of Biosimilars in Middle East 2013-2017
2.3.3 Market Analysis of Biosimilars in Africa 2013-2017
2.4 Market Development Forecast of Biosimilars in EMEA 2018-2023
2.4.1 Market Development Forecast of Biosimilars in EMEA 2018-2023
2.4.2 Market Development Forecast of Biosimilars by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Biosimilars in EMEA by Types
3.1.2 Revenue of Biosimilars in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Biosimilars in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Biosimilars in EMEA by Downstream Industry
4.2 Demand Volume of Biosimilars by Downstream Industry in Major Countries
4.2.1 Demand Volume of Biosimilars by Downstream Industry in Europe
4.2.2 Demand Volume of Biosimilars by Downstream Industry in Middle East
4.2.3 Demand Volume of Biosimilars by Downstream Industry in Africa
4.3 Market Forecast of Biosimilars in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BIOSIMILARS
5.1 EMEA Economy Situation and Trend Overview
5.2 Biosimilars Downstream Industry Situation and Trend Overview
CHAPTER 6 BIOSIMILARS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Biosimilars in EMEA by Major Players
6.2 Revenue of Biosimilars in EMEA by Major Players
6.3 Basic Information of Biosimilars by Major Players
6.3.1 Headquarters Location and Established Time of Biosimilars Major Players
6.3.2 Employees and Revenue Level of Biosimilars Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 BIOSIMILARS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Roche
7.1.1 Company profile
7.1.2 Representative Biosimilars Product
7.1.3 Biosimilars Sales, Revenue, Price and Gross Margin of Roche
7.2 Amgen
7.2.1 Company profile
7.2.2 Representative Biosimilars Product
7.2.3 Biosimilars Sales, Revenue, Price and Gross Margin of Amgen
7.3 AbbVie
7.3.1 Company profile
7.3.2 Representative Biosimilars Product
7.3.3 Biosimilars Sales, Revenue, Price and Gross Margin of AbbVie
7.4 Sanofi-Aventis
7.4.1 Company profile
7.4.2 Representative Biosimilars Product
7.4.3 Biosimilars Sales, Revenue, Price and Gross Margin of Sanofi-Aventis
7.5 Johnson & Johnson
7.5.1 Company profile
7.5.2 Representative Biosimilars Product
7.5.3 Biosimilars Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.6 Pfizer
7.6.1 Company profile
7.6.2 Representative Biosimilars Product
7.6.3 Biosimilars Sales, Revenue, Price and Gross Margin of Pfizer
7.7 Novo Nordisk
7.7.1 Company profile
7.7.2 Representative Biosimilars Product
7.7.3 Biosimilars Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.8 Eli Lilly
7.8.1 Company profile
7.8.2 Representative Biosimilars Product
7.8.3 Biosimilars Sales, Revenue, Price and Gross Margin of Eli Lilly
7.9 Novartis
7.9.1 Company profile
7.9.2 Representative Biosimilars Product
7.9.3 Biosimilars Sales, Revenue, Price and Gross Margin of Novartis
7.10 Merck
7.10.1 Company profile
7.10.2 Representative Biosimilars Product
7.10.3 Biosimilars Sales, Revenue, Price and Gross Margin of Merck
7.11 Sun
7.11.1 Company profile
7.11.2 Representative Biosimilars Product
7.11.3 Biosimilars Sales, Revenue, Price and Gross Margin of Sun
7.12 3sbio
7.12.1 Company profile
7.12.2 Representative Biosimilars Product
7.12.3 Biosimilars Sales, Revenue, Price and Gross Margin of 3sbio
7.13 Changchun High Tech
7.13.1 Company profile
7.13.2 Representative Biosimilars Product
7.13.3 Biosimilars Sales, Revenue, Price and Gross Margin of Changchun High Tech
7.14 CP Guojian
7.14.1 Company profile
7.14.2 Representative Biosimilars Product
7.14.3 Biosimilars Sales, Revenue, Price and Gross Margin of CP Guojian
7.15 Biotech
7.15.1 Company profile
7.15.2 Representative Biosimilars Product
7.15.3 Biosimilars Sales, Revenue, Price and Gross Margin of Biotech
7.16 Gelgen
7.17 Innovent
7.18 Dong Bao
7.19 Ganlee
7.20 United Laboratories
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOSIMILARS
8.1 Industry Chain of Biosimilars
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BIOSIMILARS
9.1 Cost Structure Analysis of Biosimilars
9.2 Raw Materials Cost Analysis of Biosimilars
9.3 Labor Cost Analysis of Biosimilars
9.4 Manufacturing Expenses Analysis of Biosimilars
CHAPTER 10 MARKETING STATUS ANALYSIS OF BIOSIMILARS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Biosimilars in This Report
1.2 Commercial Types of Biosimilars
1.2.1 Antibody
1.2.2 Hormone
1.2.3 Growth Factors
1.3 Downstream Application of Biosimilars
1.3.1 Tumor
1.3.2 Diabetes
1.3.3 Cardiovascular
1.3.4 Hemophilia
1.3.5 Other
1.4 Development History of Biosimilars
1.5 Market Status and Trend of Biosimilars 2013-2023
1.5.1 EMEA Biosimilars Market Status and Trend 2013-2023
1.5.2 Regional Biosimilars Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Biosimilars in EMEA 2013-2017
2.2 Consumption Market of Biosimilars in EMEA by Regions
2.2.1 Consumption Volume of Biosimilars in EMEA by Regions
2.2.2 Revenue of Biosimilars in EMEA by Regions
2.3 Market Analysis of Biosimilars in EMEA by Regions
2.3.1 Market Analysis of Biosimilars in Europe 2013-2017
2.3.2 Market Analysis of Biosimilars in Middle East 2013-2017
2.3.3 Market Analysis of Biosimilars in Africa 2013-2017
2.4 Market Development Forecast of Biosimilars in EMEA 2018-2023
2.4.1 Market Development Forecast of Biosimilars in EMEA 2018-2023
2.4.2 Market Development Forecast of Biosimilars by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Biosimilars in EMEA by Types
3.1.2 Revenue of Biosimilars in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Biosimilars in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Biosimilars in EMEA by Downstream Industry
4.2 Demand Volume of Biosimilars by Downstream Industry in Major Countries
4.2.1 Demand Volume of Biosimilars by Downstream Industry in Europe
4.2.2 Demand Volume of Biosimilars by Downstream Industry in Middle East
4.2.3 Demand Volume of Biosimilars by Downstream Industry in Africa
4.3 Market Forecast of Biosimilars in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BIOSIMILARS
5.1 EMEA Economy Situation and Trend Overview
5.2 Biosimilars Downstream Industry Situation and Trend Overview
CHAPTER 6 BIOSIMILARS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Biosimilars in EMEA by Major Players
6.2 Revenue of Biosimilars in EMEA by Major Players
6.3 Basic Information of Biosimilars by Major Players
6.3.1 Headquarters Location and Established Time of Biosimilars Major Players
6.3.2 Employees and Revenue Level of Biosimilars Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 BIOSIMILARS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Roche
7.1.1 Company profile
7.1.2 Representative Biosimilars Product
7.1.3 Biosimilars Sales, Revenue, Price and Gross Margin of Roche
7.2 Amgen
7.2.1 Company profile
7.2.2 Representative Biosimilars Product
7.2.3 Biosimilars Sales, Revenue, Price and Gross Margin of Amgen
7.3 AbbVie
7.3.1 Company profile
7.3.2 Representative Biosimilars Product
7.3.3 Biosimilars Sales, Revenue, Price and Gross Margin of AbbVie
7.4 Sanofi-Aventis
7.4.1 Company profile
7.4.2 Representative Biosimilars Product
7.4.3 Biosimilars Sales, Revenue, Price and Gross Margin of Sanofi-Aventis
7.5 Johnson & Johnson
7.5.1 Company profile
7.5.2 Representative Biosimilars Product
7.5.3 Biosimilars Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.6 Pfizer
7.6.1 Company profile
7.6.2 Representative Biosimilars Product
7.6.3 Biosimilars Sales, Revenue, Price and Gross Margin of Pfizer
7.7 Novo Nordisk
7.7.1 Company profile
7.7.2 Representative Biosimilars Product
7.7.3 Biosimilars Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.8 Eli Lilly
7.8.1 Company profile
7.8.2 Representative Biosimilars Product
7.8.3 Biosimilars Sales, Revenue, Price and Gross Margin of Eli Lilly
7.9 Novartis
7.9.1 Company profile
7.9.2 Representative Biosimilars Product
7.9.3 Biosimilars Sales, Revenue, Price and Gross Margin of Novartis
7.10 Merck
7.10.1 Company profile
7.10.2 Representative Biosimilars Product
7.10.3 Biosimilars Sales, Revenue, Price and Gross Margin of Merck
7.11 Sun
7.11.1 Company profile
7.11.2 Representative Biosimilars Product
7.11.3 Biosimilars Sales, Revenue, Price and Gross Margin of Sun
7.12 3sbio
7.12.1 Company profile
7.12.2 Representative Biosimilars Product
7.12.3 Biosimilars Sales, Revenue, Price and Gross Margin of 3sbio
7.13 Changchun High Tech
7.13.1 Company profile
7.13.2 Representative Biosimilars Product
7.13.3 Biosimilars Sales, Revenue, Price and Gross Margin of Changchun High Tech
7.14 CP Guojian
7.14.1 Company profile
7.14.2 Representative Biosimilars Product
7.14.3 Biosimilars Sales, Revenue, Price and Gross Margin of CP Guojian
7.15 Biotech
7.15.1 Company profile
7.15.2 Representative Biosimilars Product
7.15.3 Biosimilars Sales, Revenue, Price and Gross Margin of Biotech
7.16 Gelgen
7.17 Innovent
7.18 Dong Bao
7.19 Ganlee
7.20 United Laboratories
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOSIMILARS
8.1 Industry Chain of Biosimilars
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BIOSIMILARS
9.1 Cost Structure Analysis of Biosimilars
9.2 Raw Materials Cost Analysis of Biosimilars
9.3 Labor Cost Analysis of Biosimilars
9.4 Manufacturing Expenses Analysis of Biosimilars
CHAPTER 10 MARKETING STATUS ANALYSIS OF BIOSIMILARS
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
